Literature DB >> 16718705

Quantifying axonal loss after optic neuritis with optical coherence tomography.

Fiona Costello1, Stuart Coupland, William Hodge, Gianni R Lorello, Jeannie Koroluk, Y Irene Pan, Mark S Freedman, David H Zackon, Randy H Kardon.   

Abstract

OBJECTIVE: To determine to what degree changes in retinal nerve fiber layer (RNFL) thickness after optic neuritis (ON) correlate with either visual recovery or impairment.
METHODS: ON can cause visible defects within the RNFL, which can be quantified using optical coherence tomography (OCT). It may be possible to predict visual recovery by measuring RNFL loss after ON. Fifty-four patients underwent repeated evaluations with optical coherence tomography and standardized ophthalmic testing after ON. Regression analyses were used to determine the relationship between RNFL thickness and visual function.
RESULTS: Thinning of the RNFL was seen in the majority of patients (74%), and it tended to occur within 3 to 6 months of ON. The average RNFL value was thinner (p<0.0001) in the affected (78 microm) compared with the unaffected eye (100 microm). Patients with incomplete visual recovery demonstrated greater RNFL loss after ON. Regression analyses demonstrated a threshold of RNFL thickness (75 microm), below which RNFL measurements predicted persistent visual dysfunction.
INTERPRETATION: Determination of RNFL thickness may predict visual recovery after ON, and lower RNFL values correlate with impaired visual function. Optical coherence tomography may have a potential role as a surrogate marker for axonal integrity within the optic nerve among patients with ON. Ann Neurol 2006;59:963-969.

Entities:  

Mesh:

Year:  2006        PMID: 16718705     DOI: 10.1002/ana.20851

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  197 in total

Review 1.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Anatomical and functional retinal changes in multiple sclerosis.

Authors:  G Cennamo; M R Romano; E C Vecchio; C Minervino; C Della Guardia; N Velotti; A Carotenuto; S Montella; G Orefice; G Cennamo
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

3.  The photopic negative response of the flash electroretinogram in multiple sclerosis.

Authors:  Jing Wang; Han Cheng; Ying-Sheng Hu; Rosa A Tang; Laura J Frishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-09       Impact factor: 4.799

4.  A study of retinal parameters measured by optical coherence tomography in patients with multiple sclerosis.

Authors:  Sai-Jing Hu; Yi-An You; Yi Zhang
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

5.  Comparison of retinal nerve fiber layer measured by time domain and spectral domain optical coherence tomography in optic neuritis.

Authors:  G Rebolleda; A García-García; H R Won Kim; F J Muñoz-Negrete
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

6.  Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis.

Authors:  Stephanie B Syc; Shiv Saidha; Scott D Newsome; John N Ratchford; Michael Levy; E'tona Ford; Ciprian M Crainiceanu; Mary K Durbin; Jonathan D Oakley; Scott A Meyer; Elliot M Frohman; Peter A Calabresi
Journal:  Brain       Date:  2011-10-17       Impact factor: 13.501

7.  Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability.

Authors:  Hormuzdiyar H Dasenbrock; Seth A Smith; Arzu Ozturk; Sheena K Farrell; Peter A Calabresi; Daniel S Reich
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

8.  Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases.

Authors:  Gregory F Wu; Chelsea R Parker Harp; Kenneth S Shindler
Journal:  Curr Immunol Rev       Date:  2015

Review 9.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

Review 10.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.